NEU Share Price

Open 0.07 Change Price %
High 0.08 1 Day 0.00 0.00
Low 0.07 1 Week -0.02 -22.22
Close 0.07 1 Month 0.00 0.00
Volume 2137006 1 Year -0.04 -36.36
52 Week High 0.12
52 Week Low 0.04
NEU Important Levels
Resistance 2 0.08
Resistance 1 0.08
Pivot 0.07
Support 1 0.06
Support 2 0.06
ASX Australia Most Active Stocks
AGO 0.03 0.00%
AGO 0.03 0.00%
AGO 0.03 0.00%
BUR 0.02 0.00%
BUR 0.02 0.00%
BUR 0.02 0.00%
DJS 3.99 0.00%
DJS 3.99 0.00%
KSO 0.40 3900.00%
FXJ 1.09 2.83%
More..
ASX Australia Top Gainers Stocks
KSO 0.40 3900.00%
COM 0.02 100.00%
COM 0.02 100.00%
COM 0.02 100.00%
COM 0.02 100.00%
IRM 0.03 50.00%
IRM 0.03 50.00%
IRM 0.03 50.00%
BNV 0.03 50.00%
PMQ 0.03 50.00%
More..
ASX Australia Top Losers Stocks
APP 0.20 -80.00%
APP 0.20 -80.00%
APP 0.20 -80.00%
APP 0.20 -80.00%
TCQ 0.27 -73.53%
GDY 0.01 -50.00%
SRI 0.01 -50.00%
SRI 0.01 -50.00%
SRI 0.01 -50.00%
SRI 0.01 -50.00%
More..

Neuren Pharmaceuticals Ltd (ASX: NEU)

NEU Technical Analysis 1.5
As on 29th Mar 2017 NEU Share Price closed @ 0.07 and we RECOMMEND Buy for LONG-TERM with Stoploss of 0.06 & Sell for SHORT-TERM with Stoploss of 0.07 we also expect STOCK to react on Following IMPORTANT LEVELS.
NEU Target for March
1st Target up-side 0.08
2nd Target up-side 0.09
3rd Target up-side 0.1
1st Target down-side 0.06
2nd Target down-side 0.05
3rd Target down-side 0.04
NEU Other Details
Segment EQ
Market Capital 0.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.neurenpharma.com
NEU Address
NEU
697 Burke Road
Suite 201
Camberwell, VIC 3124
Australia
Phone: 61 3 9092 0480
NEU Latest News
Interactive Technical Analysis Chart Neuren Pharmaceuticals Ltd ( NEU ASX Australia )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Neuren Pharmaceuticals Ltd
NEU Business Profile
Neuren Pharmaceuticals Limited, a biopharmaceutical company, focuses on the development of therapies for brain injury, neurodevelopment, and neurodegenerative disorders primarily in the United States. Its product development pipeline includes NNZ-2566 that is in Phase II clinical trials in rett syndrome, fragile X syndrome, and moderate to severe traumatic brain injury, as well as in concussion; and NNZ-2591, which is in preclinical development for chronic neurodegenerative conditions. The company has collaborative relationship with the US Army Medical Research & Materiel Command; and the Walter Reed Army Institute of Research. Neuren Pharmaceuticals Limited is based in Camberwell, Australia.